Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis-still a long way to go! Authors' reply
- PMID: 35040167
- DOI: 10.1111/apt.16759
Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis-still a long way to go! Authors' reply
Comment on
-
Epstein-Barr virus status and immunosuppression use in paediatric autoimmune liver disease.Aliment Pharmacol Ther. 2022 Feb;55(4):455-463. doi: 10.1111/apt.16708. Epub 2021 Nov 18. Aliment Pharmacol Ther. 2022. PMID: 34796537
-
Editorial: testing for Epstein-Barr virus and treating autoimmune hepatitis-still a long way to go!Aliment Pharmacol Ther. 2022 Feb;55(3):364-365. doi: 10.1111/apt.16751. Aliment Pharmacol Ther. 2022. PMID: 35040164 No abstract available.
References
REFERENCES
-
- Bolio R, Srivastava A. Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis-still a long way to go! Aliment Pharmacol Ther. 2022;55:364-365.
-
- Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617-1625.
-
- Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621-1628.
-
- Jensen MD, Jepsen P, Vilstrup H, et al. Increased cancer risk in autoimmune hepatitis: a Danish Nationwide Cohort Study. Am J Gastroenterol. 2021. https://doi.org/10.14309/ajg.0000000000001525 [Online ahead of print].
-
- Nayagam JS, Heneghan MA, Samyn M, Joshi D. Epstein-Barr virus status and immunosuppression use in paediatric autoimmune liver disease. Aliment Pharmacol Ther. 2021; https://doi.org/10.1111/apt.16708.